Crohn’s Disease Plasma

Crohn’s Disease Plasma for Immune-Mediated Inflammatory Bowel Disease Research

Crohn’s Disease Plasma is collected from IRB-consented donors with a clinically confirmed diagnosis of Crohn’s disease and processed within one day of collection to preserve labile analytes such as cytokines, proteases, and metabolites. Crohn’s disease is an immune-mediated inflammatory bowel disease: a dysregulated mucosal immune response to the intestinal microbiota in a genetically susceptible host, rather than a classical autoantibody-driven autoimmune disease. Bulk plasma is available for higher-volume programs.

What Crohn’s Disease Plasma Reveals

• Crohn’s disease inflammation runs through the IL-12/IL-23, Th1/Th17 and TNF axis. Plasma is the practical matrix for the soluble mediators these pathways release into circulation, including TNF, IL-6, IL-17A, IL-22 and oncostatin M.
• Barrier failure and impaired intracellular bacterial handling, reflected in risk loci such as NOD2, ATG16L1 and IL23R, generate circulating markers of microbial translocation and innate immune activation that tissue-only assays do not capture.
• Anti-Saccharomyces cerevisiae antibodies (ASCA) are frequently present in Crohn’s disease. These are anti-microbial antibodies, not autoantibodies, and ASCA reactivity is used to help separate Crohn’s disease from ulcerative colitis serologically.
• Matrix metalloproteinases and extracellular matrix turnover fragments measurable in plasma reflect the transmural and fibrostenosing behaviour that distinguishes Crohn’s disease from mucosa-limited colitis.
• EDTA or citrate plasma preserves complement fragments, platelet-derived mediators and cell-free DNA that are degraded or artefactually shifted during the clotting step required to make serum.
• Trough biologic concentrations and anti-drug antibodies against anti-TNF, anti-IL-23 and anti-integrin agents are quantified in plasma or serum, supporting therapeutic drug monitoring assay development.

Donor Stratification Available

• Disease activity, including clinical remission versus active flare, with Harvey-Bradshaw Index or CDAI where documented
• Montreal classification: age at diagnosis, disease location (ileal, colonic, ileocolonic, upper GI) and behaviour (non-stricturing, stricturing, penetrating)
• Laboratory and serology results where available, including CRP, faecal calprotectin and ASCA status
• Treatment status: biologic-naive, anti-TNF, anti-IL-12/23 or anti-IL-23, anti-integrin, JAK inhibitor, corticosteroid or immunomodulator
• Surgical and complication history, including prior resection, ostomy and perianal fistulising disease
• Matched healthy controls available, as well as ulcerative colitis donors for IBD subtype comparison

Product Features

• Research Use Only (RUO)
• Plasma collected from clinically confirmed Crohn’s disease donors
• Processed within one day of collection
• Anticoagulant selection (EDTA, citrate, heparin) available on request
• IRB-approved protocols and informed consent
• Custom aliquot volumes available upon request; volumes and lot details reported per lot

De-identified Donor Data

• Verified Crohn’s disease diagnosis
• Demographic data: age, sex assigned at birth, race/ethnicity
• Donor-reported medications, allergies, and comorbidities
• Additional Crohn’s disease-specific metadata available on request

Applications

• Cytokine and inflammatory mediator profiling across the TNF and IL-23/Th17 axes
• Biomarker discovery and validation for disease activity and mucosal healing
• Plasma proteomics and metabolomics, including bile acid and tryptophan pathway work
• Assay development for therapeutic drug monitoring and anti-drug antibody detection
• Fibrosis and extracellular matrix turnover marker research in stricturing disease
• IBD subtype discrimination studies comparing Crohn’s disease and ulcerative colitis
• Cell-free DNA and extracellular vesicle isolation from plasma
• Reference material and control matrix for immunoassay qualification

Other Crohn’s Disease Specimen Types

• Crohn’s Disease Serum
• Crohn’s Disease Whole Blood
• Crohn’s Disease PBMC
• Crohn’s Disease Leukopak
• Crohn’s Disease Bulk Plasma
• Crohn’s Disease CD19+ B Cells

Compliance and Quality Assurance

• IRB-approved and HIPAA-compliant protocols
• Electronic informed consent with 21 CFR Part 11 – compliant e-signatures
• Documentation support available for regulatory review

Ordering & Customization

Crohn’s disease plasma is available in standard and custom volumes. For pricing, current availability, or a quote on a stratified donor cohort, email learnmore@sanguinebio.com. For international orders or documentation requirements, please contact us to ensure compatibility with your country’s regulations. To browse other disease states in this specimen type, visit our human plasma page.